Royal Bank Of Canada Prometheus Biosciences, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$103.46 - $126.29 $227,094 - $277,206	-2,195 Reduced 14.98%	12,454 $1.34 Million
Q4 2022 Feb 14, 2023	SELL	$36.06 - $117.21 $68,189 - $221,644	-1,891 Reduced 11.43%	14,649 $1.61 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $437,311 - $916,071	15,524 Added 1527.95%	16,540 $976,000
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $31,928 - $55,528	-1,426 Reduced 58.39%	1,016 $29,000
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $117,024 - $194,200	-3,884 Reduced 61.4%	2,442 $93,000
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $103,579 - $183,821	4,649 Added 277.22%	6,326 $251,000
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $18,884 - $24,371	904 Added 116.95%	1,677 $39,000
Q2 2021 Aug 16, 2021	BUY	$16.8 - $29.65 $12,986 - $22,919	773 New	773 $19,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.